Scarica l'app Stockscreener
9.58
0.31%
0.03
Dopo l'orario di chiusura:
9.25
-0.33
-3.44%
Precedente Chiudi:
$9.55
Aprire:
$9.63
Volume 24 ore:
658.68K
Relative Volume:
0.45
Capitalizzazione di mercato:
$293.87M
Reddito:
-
Utile/perdita netta:
$-29.25M
Rapporto P/E:
-8.0776
EPS:
-1.186
Flusso di cassa netto:
$-22.80M
1 W Prestazione:
+4.47%
1M Prestazione:
+1.16%
6M Prestazione:
+117.73%
1 anno Prestazione:
+260.15%
Intervallo 1D:
$9.45
$10.06
Intervallo di 1 settimana:
$8.6234
$10.06
Portata 52W:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Nome
Sagimet Biosciences Inc
Settore
Industria
Telefono
(650) 561-8600
Indirizzo
155 BOVET RD., SUITE 303, SAN MATEO
Confronta SGMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
9.58 | 307.47M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Iniziato | Wedbush | Outperform |
| 2025-08-07 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-24 | Iniziato | Canaccord Genuity | Buy |
| 2024-12-06 | Iniziato | Oppenheimer | Outperform |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-06-28 | Downgrade | Goldman | Buy → Neutral |
| 2024-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-25 | Iniziato | Leerink Partners | Outperform |
| 2023-08-08 | Iniziato | Goldman | Buy |
| 2023-08-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-08-08 | Iniziato | Piper Sandler | Overweight |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet Biosciences Reports Q2 Results and Clinical Progress - TipRanks
Sagimet Biosciences Q2 GAAP EPS Beats by $0.21, Cash Holdings at $135.5M - AInvest
Sagimet Biosciences: Navigating the High-Risk Biopharma Landscape with Operational Gains and Earnings Resilience - AInvest
Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates - Nasdaq
Sagimet Reports Q1 Earnings, Advances Denifanstat and TVB-3567 Trials - AInvest
Sagimet Biosciences Inc. SEC 10-Q Report - TradingView
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Wedbush Initiates Sagimet Biosciences at Outperform With $28 Price Target - MarketScreener
Wedbush initiates coverage on Sagimet Biosciences stock with Outperform rating - Investing.com Australia
Can Sagimet Biosciences Inc. Escape Recent Bear ChannelDay Trading Signals With High Precision Reviewed - beatles.ru
Sagimet Biosciences SGMT Q2 2025 Earnings Preview Upside Potential Driven by Strategic Innovations - AInvest
Is This a Bottoming Phase for Sagimet Biosciences Inc.Capital Protection Trading Strategies Gain Interest - beatles.ru
Can volume confirm reversal in Sagimet Biosciences Inc.Chart Driven Entry Timing for Swing Trades - Newser
Sagimet Biosciences Inc. Matches Institutional Buying FilterWeekly Chart Analysis With Entry Advice Provided - beatles.ru
How to recover losses in Sagimet Biosciences Inc. stockMachine Learning Intraday Signal Forecast - Newser
How to build a dashboard for Sagimet Biosciences Inc. stockShort-Term Upside Breakout Forecast System - Newser
How sentiment analysis helps forecast Sagimet Biosciences Inc.Market Opportunity Tracker for Swing Traders - Newser
Can Sagimet Biosciences Inc. recover in the next quarterFree Long Hold Safe Return Strategy - Newser
Sagimet Biosciences assumed with a Buy at H.C. Wainwright - TipRanks
Promising Prospects for Sagimet Biosciences: Buy Rating Backed by Innovative FASN Inhibitor Platform and Clinical Advancements - TipRanks
HC Wainwright maintains Buy rating for Sagimet Biosciences with $29 PT. - AInvest
What makes Sagimet Biosciences Inc. stock price move sharplyPre-Market Stock Movement Summary and Review - Newser
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Clinical-Stage Biotech Sagimet to Share Latest Therapeutic Developments at Major Growth Conference - Stock Titan
Sagimet Biosciences Inc. Testing Reversal Zone on Weekly ChartAlpha Focused Technical Trade Signals Gain Attention - beatles.ru
Is Sagimet Biosciences Inc. a good long term investmentInvest confidently with real-time updates - Jammu Links News
Risk adjusted return profile for Sagimet Biosciences Inc. analyzedMomentum Prediction Based on AI Backtesting - Newser
Is Sagimet Biosciences Inc. stock overvalued or undervaluedMaximize your returns with expert insights - Jammu Links News
What drives Sagimet Biosciences Inc. stock priceCapitalize on momentum-driven investment opportunities - Jammu Links News
Is it the right time to buy Sagimet Biosciences Inc. stockUnstoppable trading performance - Jammu Links News
Should I hold or sell Sagimet Biosciences Inc. stock in 2025Build wealth with high-performing stocks - Jammu Links News
How volatile is Sagimet Biosciences Inc. stock compared to the marketBuild a winning investment strategy - Jammu Links News
How does Sagimet Biosciences Inc. compare to its industry peersBuild wealth faster with consistent investment plans - Jammu Links News
How many analysts rate Sagimet Biosciences Inc. as a “Buy”Build a winning portfolio with smart picks - Jammu Links News
What catalysts could drive Sagimet Biosciences Inc. stock higher in 2025Explosive trading growth - Jammu Links News
What are the technical indicators suggesting about Sagimet Biosciences Inc.Unlock exclusive trading strategies for gains - Jammu Links News
Wyckoff Accumulation Phase Possible in Sagimet Biosciences Inc.Entry Alert Based on Volume Spikes Detected - metal.it
What are the latest earnings results for Sagimet Biosciences Inc.Swing Trade Updates To Watch Now - Jammu Links News
Can Sagimet Biosciences Inc. hit a new high this monthTrade Setups With Clear Risk Limits Highlighted - metal.it
Why Sagimet Biosciences Inc. stock attracts strong analyst attentionEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Sagimet Biosciences Inc. Stock Performance After Earnings: Historical InsightsWeekly Portfolio Update with ROI Focus - Newser
How high can Sagimet Biosciences Inc. stock price go in 2025Daily Stock Forecast Powered by AI Tools - Newser
How Sagimet Biosciences Inc. stock performs during market volatilityCommunity Strategy With High Win Rate Backtested - metal.it
Custom watchlist performance reports with Sagimet Biosciences Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
Sagimet Biosciences Inc. Enters Reversal Setup in Weekly ChartsLow Volatility Stable Growth Picks Rank High - metal.it
Is Sagimet Biosciences Inc. stock reversal real or fakeMulti-Year Signal Summary and Entry Timing - Newser
Chart Patterns Forming a Bullish Setup in Sagimet Biosciences Inc.Investment Plan With Growth Optimization Finalized - metal.it
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $26.83 Consensus Target Price from Brokerages - Defense World
Sagimet Biosciences Inc Azioni (SGMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):